1. Low-intensity pulsed ultrasound ameliorates cardiac diastolic dysfunction in mice: a possible novel therapy for heart failure with preserved left ventricular ejection fraction
- Author
-
Yuto Monma, Ryo Kurosawa, Yosuke Ikumi, Haruka Sato, Takashi Nakata, Hiroaki Shimokawa, Sadamitsu Ichijo, Yutaka Kagaya, Masahito Miura, Satoshi Miyata, Ayana Matsumoto, Tomohiko Shindo, Hiroshi Kanai, and Kumiko Eguchi
- Subjects
medicine.medical_specialty ,Nitric Oxide Synthase Type III ,Physiology ,Ultrasonic Therapy ,Diastole ,Hemodynamics ,Low-intensity pulsed ultrasound ,Nitric Oxide ,Placebo ,Ventricular Function, Left ,Angina ,Ventricular Dysfunction, Left ,Physiology (medical) ,Internal medicine ,Cyclic GMP-Dependent Protein Kinases ,medicine ,Animals ,Myocytes, Cardiac ,Calcium Signaling ,Mice, Knockout ,Heart Failure, Diastolic ,Ejection fraction ,business.industry ,Isolated Heart Preparation ,Stroke Volume ,medicine.disease ,Fibrosis ,Intensity (physics) ,Disease Models, Animal ,Ultrasonic Waves ,Heart failure ,Cardiology ,Receptors, Leptin ,Cardiology and Cardiovascular Medicine ,business - Abstract
Aims Heart failure with preserved LV ejection fraction (HFpEF) is a serious health problem worldwide, as no effective therapy is yet available. We have previously demonstrated that our low-intensity pulsed ultrasound (LIPUS) therapy is effective and safe for angina and dementia. In this study, we aimed to examine whether the LIPUS therapy also ameliorates cardiac diastolic dysfunction in mice. Methods and results Twelve-weeks-old obese diabetic mice (db/db) and their control littermates (db/+) were treated with either the LIPUS therapy (1.875 MHz, 32 cycles, Ispta (spatial peak temporal average intensity) 117-162 mW/cm2, 0.25 W/cm2) or placebo procedure 2 times a week for 4 weeks. At 20-week-old, transthoracic echocardiography and invasive hemodynamic analysis showed that cardiac diastolic function parameters, such as e', E/e', end-diastolic pressure-volume relationship, Tau, and dP/dt min, were all deteriorated in placebo-treated db/db mice compared with db/+ mice, while systolic function was preserved. Importantly, these cardiac diastolic function parameters were significantly ameliorated in the LIPUS-treated db/db mice. We also measured the force (F) and intracellular Ca2+ ([Ca2+]i) in trabeculae dissected from ventricles. We found that relaxation time and [Ca2+]i decay (Tau) were prolonged during electrically stimulated twitch contractions in db/db mice, both of which were significantly ameliorated in the LIPUS-treated db/db mice, indicating that the LIPUS therapy also improves relaxation properties at tissue level. Functionally, exercise capacity was also improved in the LIPUS-treated db/db mice. Histologically, db/db mice displayed progressed cardiomyocyte hypertrophy and myocardial interstitial fibrosis, while those changes were significantly suppressed in the LIPUS-treated db/db mice. Mechanistically, Western blot showed that the eNOS-NO-cGMP-PKG pathway and Ca2+-handling molecules were up-regulated in the LIPUS-treated heart. Conclusions These results indicate that the LIPUS therapy ameliorates cardiac diastolic dysfunction in db/db mice through improvement of eNOS-NO-cGMP-PKG pathway and cardiomyocyte Ca2+-handling system, suggesting its potential usefulness for the treatment of HFpEF patients. Translational perspective Although HFpEF is a serious health problem worldwide, no effective treatment is yet available. We have previously demonstrated that our low-intensity pulsed ultrasound (LIPUS) therapy is effective and safe in animal models of angina and dementia. In this study, we examined whether our LIPUS therapy is also effective to improve cardiac diastolic dysfunction in mice. We found that the LIPUS therapy ameliorated myocardial structures and Ca2+-handling proteins, resulting in the improvement of cardiac diastolic functions and exercise tolerance in a mouse model of HFpEF. These results suggest that the LIPUS therapy is useful for the treatment of HFpEF in humans.
- Published
- 2020